Join us for an educational workshop on the diagnosis, treatment and monitoring of plasma cell malignancies, including current practices and opportunities for improvement.

The workshop will include lectures plus roundtable discussions around the most hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

Numerous networking opportunities will also be available in order to establish potential collaborations among speakers and participants.

In support of improving patient care, this activity has been planned and implemented by Mayo Clinic College of Medicine and Science and International Myeloma Society. Mayo Clinic College of Medicine and Science is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Friday, July 27, 2018

07:45-8:00  Welcome and Introduction
            Jesús San Miguel, MD and Vânia Hungria, MD

08:00-08:30  The myeloma pathogenesis with focus on the immune system
            Ivan Borello, MD

08:30-9:00  Genetics in MM patients
            Norma Gutiérrez, MD

09:00-09:30  What are the optimal Imaging Techniques in MM? MRI, CT-scan and PET?
            María-Victoria Mateos, MD

09:30-10:00  Coffee Break

10:00-10:30  How to perform an appropriate protein screening and decisions on follow-up?
            Joan Bladé, MD

10:30-11:00  Minimal residual Disease. How and when to do it?
            Jesús San Miguel, MD

11:00-12:00  Roundtable: How to do a correct diagnosis and follow-up, including the new diagnostic and response criteria
            Moderator: Jesús San Miguel, MD
            Discussants: Angelo Maiolino, MD, Pedro Zarate, MD, Joan Bladé, MD, Norma Gutiérrez, MD,
            Jesus Berdeja, MD, Guillermo Conte, MD

12:00-13:00  Lunch

13:00-13:30  MGUS & Smouldering Myeloma: How to predict outcome & “To treat or not to treat”
            María-Victoria Mateos, MD

13:30-14:00  How I treat newly diagnosed transplant candidate MM patients
            Sergio Giralt, MD

14:00-15:00  Roundtable on 6 controversial questions with emphasis in local practice
            Moderator: Sergio Giralt, MD
            Discussants: David Gómez Almaguer, MD, Vânia Hungria, MD, Jose Luis Lopez, MD, Sergio Giralt, MD,
            Jesús San Miguel, MD, Timoleon Anguita, MD

1) Best induction
2) Early vs. late transplant
3) One or two
4) Consolidation
5) Maintenance
6) Allotransplant

15:00-15:30  Coffee Break

15:30-16:00  How I treat newly diagnosed elderly patients?
            Ruben Niesvizky, MD
16:00-17:00  **Roundtable on 5 controversial questions with emphasis in local practice**  
**Moderator:** María-Victoria Mateos, MD  
**Discussants:** Roberto Pessoa, MD, Eloisa Riva, MD, Natalia Schultz, MD, Sergio Giralt, MD, Joan Bladé, MD, Ruben Niesvizky, MD  
1) Optimal combinations  
2) Fixed versus continuous therapy  
3) Do we need alkylators?  
4) High risk  
5) Frailty

17:00 – 17:45  **Keynote Lecture: The future of immunotherapy in Myeloma (Basic Concepts)**  
**Jesus Berdeja, MD**  
**Introduced by Ivan Borrello, MD**

---

**Saturday, July 28, 2018**

8:15-9:00  **Treatment of Disease Complications**  
**Jorge Castillo, MD**

9:00-9:30  **How to make the right choices in the relapsed patient**  
**Enrique Ocio, MD**

9:30-10:30  **Roundtable on 5 clinical cases with emphasis in local practice**  
**Moderator:** Jesús San Miguel, MD  
**Discussants:** Edvan Crusoe, MD, Dorotea Fantl, MD, Amado Karduss, MD, Enrique Ocio, MD, Ruben Niesvizky, MD, Jesus Berdeja, MD, Juan Ramon Navarro, MD

10:30-11:00  **Coffee Break**

11:00-11:30  **Amyloidosis: “Under-diagnosed disorder”**  
**Joan Bladé, MD**

11:30-12:00  **Waldenström Macroglobulinemia**  
**Jorge Castillo, MD**

12:00  **Lunch**

---

**THANK YOU TO OUR SPONSORS**

**Gold**

**Silver**

**Additional Support Provided By**

Bristol-Myers Squibb Imuno-Oncologia